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LysosomeOxidative phosphorylation system (OXPHOS) deﬁciencies are rare diseases but constitute the most frequent in-
born errors of metabolism.We analyzed the autophagy route in 11 skin ﬁbroblast cultures derived from patients
with well characterized and distinct OXPHOS defects. Mitochondrial membrane potential determination re-
vealed a tendency to decrease in 5 patients' cells but reached statistical signiﬁcance only in 2 of them. The remain-
ing cells showed either no change or a slight increase in this parameter. Colocalization analysis of mitochondria
and autophagosomes failed to show evidence of increased selective elimination of mitochondria but revealed
more intense autophagosome staining in patients' ﬁbroblasts comparedwith controls. Despite the absence of in-
creased mitophagy, Parkin recruitment to mitochondria was detected in both controls' and patients' cells and
was slightly higher in cells harboring complex I defects. Western blot analysis of the autophagosome marker
LC3B, conﬁrmed signiﬁcantly higher levels of the protein bound to autophagosomes, LC3B-II, in patients' cells,
suggesting an increased bulk autophagy in OXPHOS defective ﬁbroblasts. Inhibition of lysosomal proteases
caused signiﬁcant accumulation of LC3B-II in control cells, whereas in patients' cells this phenomenon was less
pronounced. Electron microscopy studies showed higher content of late autophagic vacuoles and lysosomes in
OXPHOS defective cells, accompanied by higher levels of the lysosomal marker LAMP-1. Our ﬁndings suggest
that in OXPHOS deﬁcient ﬁbroblasts autophagic ﬂux could be partially hampered leading to an accumulation
of autophagic vacuoles and lysosomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autophagy is a route of degradation of cellular components that can
be induced by different stimuli. Several forms of autophagy exist and
among them, macroautophagy (hereafter autophagy), involves the
formation of double-membrane vesicles called autophagosomes that
enwrap and sequester the cellular component to be eliminated (for a
review see [1]). After cargo sequestration, autophagosomes fuse with
lysosomes that will digest the sequestered material, allowing recycling
of some of its components or supporting energy production. This type
of autophagy is, so far, the only known route to clear large structures
and entire organelles, such as mitochondria. Although this pathway
was mainly considered as a bulk sequestration process, selective au-
tophagy to degrade excessive or damaged organelles was initiallydades raras: mitocondriales y
Universitario 12 de Octubre
venida de Córdoba s/n, 28041described by Kissova et al. [2], and to emphasize the non-random elim-
ination of defective mitochondria, the term mitophagy was proposed
[3]. In recent years mitophagy has been related to the dissipation of mi-
tochondrialmembrane potential (ΔΨ),which could trigger the elimina-
tion of the organelle [2,4–8]. Since the beginning of this century it has
been highlighted thatmitochondria are dynamic organelles that contin-
uously fuse and divide. These processes, generally termedmitochondri-
al dynamics, ﬁne-tune fundamental cellular pathways, and alterations
in them can constitute both cause and effect of disease [9]. It has been
proposed that after ﬁssion, if the resulting mitochondria are dysfunc-
tional and not able to repolarize, fusion is impaired and mitochondria
are kept in an isolated state in which they are tagged and recruited for
digestion and elimination by autophagy [2,4–8,10,11]. Thus, autophagy
and mitochondrial dynamics would cooperate to target dysfunctional
mitochondria for elimination and would help in maintaining the bio-
energetic efﬁciency of the cell. Nevertheless, the selective inhibition of
mitochondrial fusion by mitochondrial dysfunction has been only
demonstrated in yeast [12], and how mitochondrial dynamics could
aid in the elimination of dysfunctional mitochondria is still a matter of
research.
1060 M. Morán et al. / Biochimica et Biophysica Acta 1842 (2014) 1059–1070Primary mitochondrial diseases (MD) caused by dysfunction of the
oxidative phosphorylation system (OXPHOS) are the most frequent
inborn errors of metabolism. Cells from MD patients show decreased
ΔΨ due to diminished electron ﬂow through the respiratory chain
[13–18], suggesting that the selective elimination of defective mito-
chondria in cells from patients with MD could be increased. Neverthe-
less, this possibility has not been studied in depth. In fact, only three
reports exist describing increased mitophagy in cells from patients
with primary coenzyme Q deﬁciency and patients with coenzyme Q
deﬁciency associated with mutations in mitochondrial DNA (mtDNA)
[19–21]. In tissues from animal models of MD evidence of increased au-
tophagy has been reported. For instance, in amousemodel ofmitochon-
drial myopathy due to mutation in the mitochondrial helicase Twinkle,
evidence of an increased autophagic starvation-like response, involving
mitophagy in skeletalmuscle, has been described [22,23]. In addition, in
a murine model of dominant optic atrophy, an increased amount of
autophagosomes was found in retinal ganglion cells [24]. These evi-
dences support the hypothesis that mitochondrial deﬁciency could
induce a stress signal leading to increased autophagy as compensatory
response, either to obtain energy or to eliminate damagedmitochondria
that could induce further cellular dysfunction.
The goal of our studywas to evaluate the autophagic response in pri-
mary skin ﬁbroblasts derived from 11MD patients, with well character-
ized and distinct mutations in nuclear and mitochondrial OXPHOS
genes, and to further analyze the role ofmitophagy in the pathophysiol-
ogy of MD. These cells were divided in 4 differentiated groups attending
to the respiratory chain deﬁciency they presented: (i) ﬁbroblasts with
isolated complex I deﬁciency due to mutations in NDUFV1 and
NDUFA1 (n = 3); (ii) ﬁbroblasts with complex III deﬁciency harboring
mutations in the complex III assembly factor BCS1L (n = 5); (iii) ﬁbro-
blasts with mutations in the complex IV assembly factor SURF1 and in
the mitochondrial encoded complex IV gene COX2 (n = 2); and
(iv) one cell line with decreased mitochondrial content due to muta-
tions in SUCLG1.
2. Materials and methods
2.1. Cell culture and treatments
Skin ﬁbroblasts fromMDpatients were cultured in DMEMwith high
glucose (4.5 g/L) supplemented with 10% fetal calf serum, penicillin
50 IU/mL and streptomycin 50 IU/mL. Cells were routinely checked to
be free of mycoplasms.
Respiratory chain (RC) deﬁciency detected in each cell line and the
patients' (P) main genetic data are shown in Table 1. Cell lines from
P1 to P3 showed isolated complex I deﬁciency due to mutations either
in the complex I catalytic subunit NDUFV1 or in the structural subunit
NDUFA1 [25,26]. Cell lines from P4 to P6 and P8 showed either isolated
or combined complex III deﬁciency due to mutations in the complex III
assembly factor BCS1L [27–30], whereas P7 did not show signiﬁcant
alteration of RC activities in ﬁbroblasts but decreased complex III inTable 1
Respiratory chain deﬁciency determined in ﬁbroblasts from patients withMD and patients' ma
zygosis.
Fibroblasts line RC complex deﬁciency Gene
Patient 1 (P1) Complex I NDUFV1
Patient 2 (P2) Complex I NDUFA1
Patient 3 (P3) Complex I NDUFA1
Patient 4 (P4) Complex II, III, IV BCS1L
Patient 5 (P5) Complex I, III BCS1L
Patient 6 (P6) Complex I, III, IV BCS1L
Patient 7 (P7) None BCS1L
Patient 8 (P8) Complex III BCS1L
Patient 9 (9) Complex IV SURF-1
Patient 10 (P10) Complex IV COXII
Patient 11 (P11) Complexes III, IV, I + III SUCLG1skeletal muscle [30]. P9 and P10 showed complex IV deﬁciency due to
mutations in the assembly factor SURF1 and in the structural subunit
COX2 respectively, the latter showing 60% heteroplasmy [31]. The com-
bined RC deﬁciency found in P11 was due to decreased levels of mito-
chondrial DNA caused by mutations in SUCLG1 [32].
We have studied ﬁbroblasts from skin biopsies obtained for research
purposes afterwritten informed consent. The researchwas approved by
the Ethics Committee atHospital 12 de Octubre and is in accordancewith
the Helsinki Declaration.
To analyze autophagy-dependent degradation of LC3, cells were
maintained in a culture medium with freshly prepared E64d and
pepstatin A (Sigma) at 10 μg/mL in DMSO for 4 h according to Kimura
et al. [33]. Cells werewashedwith ice-cold PBS, scraped and centrifuged
at 800 ×g for 5 min at 4 °C. Cells were subsequently resuspended in a
lysis buffer and Western blot analysis was performed to detect LC3B
as described below.
2.2. Western blot analysis in cell lysates
Fibroblasts were lysed in 5mMTris pH 8.0, 20mMEDTA, 0.5% Triton
X-100, protease and phosphatase inhibitor cocktail (Roche), centrifuged
at 11,000 ×g, and supernatant was collected. Protein content of the su-
pernatants (cell lysates) was determined [34]. Samples of cell lysates
(5–10 μg) were used to perform semi-quantitative analysis, by Western
Blot, of the levels of: LC3B (anti-LC3B Sigma), LAMP-1 (anti-LAMP-1 G1/
139/5, DHSB), and pyruvate dehydrogenase E1 alpha (PDH-E1-α), com-
plex II 70 kDa subunit (SDHA), and Complex Vα subunit (CVα), all from
Mitosciences. Immunodetection of primary antibodies was carried out
with peroxidase-conjugated secondary antibodies (GE Healthcare). The
signal was detected with Enzyme Chemiluminiscence (Novex® ECL
HRP Chemiluminiscent Substrate Reagent Kit, Life Technologies S.A.).
Band densities were evaluated by densitometric scanning (Image J soft-
ware). β actin or α tubulin were immunodetected with mouse anti-β
actin and anti-α tubulin (both from Sigma) and used as loading control.
2.3. ATP content measurements
Cellular ATP was extracted from cells in boiling 100 mM Tris, 4 mM
EDTA pH 7.75, and assayed by bioluminescence using a luciferin-
luciferase system (Roche) according to manufacturer's instructions.
ATP concentration was corrected by cell number and expressed as per-
centage of control cells' ATP content.
2.4. Confocal microscopy in living cells
Mitochondrial membrane potential (ΔΨ) was analyzed by confocal
microscopy in living cells as described by Davidson et al. [35]. In brief,
plasma membrane was depolarized by the addition of potassium to
50mMand cells were loadedwith 30 nM tetramethylrhodaminemeth-
yl ester (TMRM) for 60min in a CO2 incubator. Image collectionwas car-
ried out in cells maintained at 37 °Cwith a 40× lens using 543 nm laserin genetic data. In patient 7 (P7), only the p.R184Cmutation in BCS1Lwas found in hetero-
Mutations Reference
[p.W51] + [p.T423M] [26]
[p.R37S] [25]
[p.G8R] [25]
[p.R56X] + [g.1181 A N G, g.1164 C N G] [29]
[p.R56X] + [p.R45C] [27]
[p.P99L] + [p.P99L] [30]
[p.R184C] + [?] [30]
[p.T50A] + [p.T50A] [28]
[p.R250X] + [p.R250X] Unpublished
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Fig. 1. A) Mitochondrial membrane potential determined by confocal microscopy
expressed as mean TMRM ﬂuorescence per cell normalized by citrate synthase activity
in control ﬁbroblasts (C) and ﬁbroblasts from patients with isolated complex I deﬁciency
(P1–P3), complex III deﬁciency (P4–P8), complex IV deﬁciency (P9, P10) and decreased
mtDNA content (P11). Data presented are mean ± SD (n = 3–8). Four different controls
were analyzed. Kruskal–Wallis test: signiﬁcant cell line effect (P= 0.047). * P b 0.05 sig-
niﬁcantly different of C. B) ATP content in controls (C), and cells showing complex III de-
ﬁciency (P4–P8) and decreased mtDNA content (P11). Data are presented as mean ± SD
(n= 3–5). Four control cell lineswere analyzed.Mann–Whitney test P=0.01 for patients
vs. controls.
1061M. Morán et al. / Biochimica et Biophysica Acta 1842 (2014) 1059–1070set at 1.5% intensity. TMRM intensity per cell was analyzed with the
Image J software and corrected by citrate synthase activity, a classical
marker of cellular mitochondrial content that was determined in cul-
tured cells as described elsewhere [36].
To evaluate lysosomal content living ﬁbroblasts were loaded with
50 nM Lysotracker™ DND-26 (Molecular Probes) for 90 min in the
dark in a CO2 incubator. Image collection was carried out with a 40×
lens using the 488 nm excitation laser line set at 2% intensity, with
cells maintained at 37 °C. Cells were imaged randomly with 1 μm slices
and 1024 × 1024 pixel resolution. Lysotracker intensity per cell was
analyzed with the Image J software. No enhancement of the original
images was done.
2.5. Immunoﬂuorescence
Immunoﬂuorescence was performed on sub-conﬂuent
paraformaldehyde-ﬁxed cells. Mouse monoclonal anti-C Vα
(MitoSciences), and rabbit anti-LC3B or anti-Parkin (Sigma) were
used as primary antibodies. Texas Red-conjugated anti-mouse
(MitoSciences) and Alexa-488-conjugated anti rabbit were used
as secondary antibodies. Coverslips were mounted in ProLong
Gold© antifade reagent (Molecular Probes) on glass slides. Cells
were viewed with a Zeiss LSM 510 Meta confocal microscope
with a 63× Plan Apochromat oil immersion objective (NA: 1.42),
sequential scanning of green and red channels was performed to
avoid bleed-through effect. Cells were imaged randomly with
0.5–0.7 μm slices and 1024 × 1024 pixel resolution. For
colocalization analysis we used the plugin “Colocalization” and
the plugin “JaCOP” to determine Manders' coefﬁcients, both from
the Image J software. No enhancement of the original images was
done.
2.6. Electron microscopy (EM)
Adherent non-conﬂuent cells were ﬁxed in 2% glutaraldehyde and 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for 90min
at room temperature,washedwith PBS and thenpost-ﬁxed in 1%OsO4 for
1 h at 4 °C. After dehydration in graded series of ethanol, the cells were
embedded in Epon812 (Fluka) andpolymerized at 60 °C for 2 days. Ultra-
thin sections (90 nm) were analyzed in a JEOL JEM1010 transmission
electronmicroscope equippedwith a 4K× 4K TemCam-F416 digital cam-
era (TVIPS, Gauting, Germany). Identiﬁcation of autophagosomes, late au-
tophagic vesicles, lysosomes and estereological counting was performed
as described previously [37–40].
2.7. Data analysis
All experiments, except electron microscopy, were performed at
least in triplicate. Data are presented as mean ± standard deviation
(SD). Six different control primary skin ﬁbroblasts were used in the
present study and 4 to 6 different controls were evaluated for the deter-
mination of each parameter. Due to the poor growth rate of patients'
cells not all the determinations could be performed in all patients' cell
lines. Statistical analysis was performed with the SPSS software (SPSS,
Chicago, IL) and statistical signiﬁcance was set at P b 0.05. When
Kruskal–Wallis test was applied, to minimize the risk of statistical
error type 1, after post hoc analysis we only performed comparison be-
tween control and patients' groups. Densitometry of Western blots
and confocal images analysis was performed with the Image J software
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://imagej.nih.gov/ij/, 1997–2012). To perform the
analysis of lysosomal ﬂux, LC3B-II/actin ratio in non-treated cells was
set as basal values of the autophagic marker for each cell line, and
increases in LC3B-II/actin in protease inhibitors-treated cells were
expressed as a percentage of its basal values.3. Results
3.1. Mitochondrial dysfunction causes mild alterations in mitochondrial
membrane potential and decreased ATP content
To assess if ΔΨ is lower in the MD cells and mitophagy could be in-
duced, we determined this parameter by confocal microscopy as mean
TMRM ﬂuorescence per cell in eleven MD primary skin ﬁbroblasts
showing: complex I deﬁciency due to mutations in NDUFV1 and
NDUFA1 (P1–P3), complex III deﬁciency caused by mutations in the as-
sembly factor of this complex, BCS1L (P4–P8), two cell types withmuta-
tions in the complex IV assembly factor SURF1 and the mitochondrial
encoded complex IV gene COX2 (P9, P10), and one cell culture with
decreased mitochondrial content due to mutations in SUCLG1 (P11)
(Fig. 1A). Statistical analysis demonstrated a signiﬁcant cell line effect
(Kruskal–Wallis test P = 0.047). Mean ΔΨ was decreased in P1, P3
and P8–P11, and post-hoc analysis revealed signiﬁcantly lower levels
in P9 and P10, both affected by complex IV deﬁciencies. On the contrary,
a slight hyperpolarization was detected in P4 and P5, both affected by a
complex III enzymatic defect.
We have previously shown that in the CI-deﬁcient cells analyzed in
the present investigation ATP content is signiﬁcantly lower compared
to control cells [26]. To assess the bionergetic state in the remaining
MD cells we also determined the ATP content, ﬁnding, in agreement,
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and P11 (Fig. 1B,Mann–Whitney test P=0.01 for patients vs. controls).
3.2. Mitochondrial dysfunction induces increased autophagic response but
does not alter mitophagy
Mitophagy was assessed in MD cell lines, by confocal microscopy
analysis of mitochondria labeled with an antibody against complex V
α subunit (CVα), and autophagosomes labeledwith an antibody against
the classical marker of these structures, LC3B [41]. The autophagosome
staining pattern revealed a more intense signal in MD cells in compari-
son with control cells, regardless of their mean mitochondrial
membrane potential, displaying LC3 puncta and also patched signal
(Fig. 2). Nevertheless, colocalizations between fragmented mitochon-
dria and autophagosomes were very scarce, even in cells with high
amounts of fragmented mitochondria, i.e. from P8. Only in few cases
small dotted mitochondria colocalized with LC3 puncta, and most of
the colocalization detected occurred in reticular mitochondria suggest-
ing that only a small number of fragmented mitochondria were beingFig. 2. Immunoﬂuorescence to detect the autophagosomal marker LC3B (green) and the mitoc
patients with isolated complex I deﬁciency (P1–P3), complex III deﬁciency (P4–P8), complex IV
white. P6 Inset: enlarged area showing colocalization of small fragmented mitochondria and aselectively eliminated (see Fig. 2, P6 inset). Colocalization according to
Mander's coefﬁcients, was low in both controls and MD cells, although
a slight increase in Mander's coefﬁcient for the green channel in
patients' ﬁbroblasts was detected (Mander's coefﬁcients for the red
channel were 0.128 ± 0.09 for controls' cells and 0.093 ± 0.08 for MD
cells, and Mander's coefﬁcients for the green channel were 0.154 ±
0.08 for controls' cells and 0.234± 0.13 for MD cells). Images of control
and MD ﬁbroblasts with both channels separately depicted are shown
in Supplemental Fig. 1A and B, also the quantitative analysis of
mean LC3B ﬂuorescence per cell is shown in Supplemental Fig. 1C
(Mann–Whitney test P= 0.014 for patients vs. controls). These ﬁndings
would indicate that bulk autophagy is higher than normal in MD ﬁbro-
blasts, but this phenomenon is not due to augmented elimination of
defective mitochondria.
As CVαwas used as a mitochondrial marker in our immunoﬂuores-
cence assays, we tested the levels of this protein in the MD cells to ex-
clude putative alterations in the mitochondrial network staining that
could bias our ﬁndings. Western blot analysis showed that CVα levels
were not decreased by the OXPHOS deﬁciencies present in our MDhondrial marker complex V α subunit (red) in control ﬁbroblasts (C) and ﬁbroblasts from
deﬁciency (P9, P10) and decreasedmtDNA content (P11). Colocalized pixels are shown in
utophagosomes. Five different controls were analyzed. 63× Plan-Apochromat objective.
A
P11C C
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Fig. 3. A) Western blot analysis of complex V α subunit (CVα) in control ﬁbroblasts
(C) and ﬁbroblasts from patients with isolated complex I deﬁciency (P1–P3), complex III
deﬁciency (P4–P8), complex IV deﬁciency (P9, P10), and decreased mtDNA content
(P11). β-actin was used as loading control. B) Levels of the key mitochondrial proteins,
complex II 70 kDa subunit (SDHA) and pyruvate dehydrogenase E1-α subunit (PDH-E1-
α) in control ﬁbroblasts (C) and ﬁbroblasts frompatients with isolated complex I deﬁcien-
cy (P1–P3), complex III deﬁciency (P4–P8), complex IV deﬁciency (P9, P10), and de-
creased mtDNA content (P11). α-tubulin was used as loading control. C) Representative
Western blot against SDHA,CVα, PDH-E1-α in six different control cell lines (C1–C6)
and complex I and complex III-deﬁcient cells (P1, P4) with their respective loading con-
trols (β-actin for SDHA and CVα, and α-tubulin for PDH-E1-α).
1063M. Morán et al. / Biochimica et Biophysica Acta 1842 (2014) 1059–1070cells (Fig. 3A). If increasedmitophagy occurred due to OXPHOS deﬁcien-
cy, we could expect lower mitochondrial content in the MD cells
compared with those of healthy controls. The previous data from our
laboratory have shown that the levels of several keymitochondrial pro-
teins (SDHA, CORE2, COX2) were not generally lower than normal in
ﬁbroblasts P2–P8, suggesting that their mitochondrial content was nei-
ther affected [25,26,30]. To further corroborate that mitochondrial con-
tent was not altered in any of the MD cells studied in the present work
we analyzed the levels of keymitochondrial proteins, such as complex II
70 kDa subunit (SDHA) and the mitochondrial matrix protein pyruvate
dehydrogenase E1-alpha (PDH-E1-α) because these proteins are com-
monly used as mitochondrial content markers. The levels of these pro-
teins were not signiﬁcantly lower in the MD cells compared with the
controls (Fig. 3B). Analysis of the densitometry of CVα, SDHA and
PDH-E1-α are shown in Supplemental Fig. 2. Levels of SDHA, CVα and
PDH-E1-α in 6 different control ﬁbroblasts and 2 MD cells (P1 and P4)
are shown in Fig. 3C. These ﬁndings suggest that themitochondrial con-
tent is not altered in any of MD cells analyzed, in agreement with the
previous research from our group [26].
We also checked the levels of protein markers for other organelles
(peroxisomes, endoplasmic reticulum and Golgi apparatus), but overall
we did not detect lower values in the MD cells studied (Supplemental
Fig. 3). These results indicate that increased autophagy in the MD ﬁbro-
blasts does not seem to induce the speciﬁc elimination of any organelle,
i.e., mitochondria, peroxisomes, endoplasmic reticulum, or Golgi
apparatus.
To analyze if the absence of mitophagy in MD-derived ﬁbroblasts
could be due to defective recruitment of dysfunctional mitochondria to
autophagy, we studied the molecular labeling of mitochondria with
Parkin (Fig. 4). The analysis of double-stained cells with anti-Parkin
and anti-CVα antibodies showed punctated Parkin signal. ColocalizationbetweenParkin andmitochondriawas evident, in fragmented and isolat-
ed mitochondria, and also in mitochondria of tubular shape in both con-
trol and MD ﬁbroblasts. Images of control and MD ﬁbroblasts with both
channels separately depicted are shown in Supplemental Fig. 4A and B.
Interestingly, ﬁbroblasts affected by complex I deﬁciency (P1–P3)
showed more intense Parkin staining in tubular mitochondrial net-
work than control cells. Mander's coefﬁcients for the red channel
were 0.537 ± 0.2 (control ﬁbroblasts), 0.642 ± 0.014 (P1), 0.768 ±
0.06 (P2) and 0.880±0.01 (P3).Mander's coefﬁcients for the green chan-
nel were 0.280 ± 0.07 (control ﬁbroblasts); 0.272 ± 0.05 (P1); 0.233 ±
0.06 (P2) and 0.151 ± 0.02 (P3).
Although we could not ﬁnd increased mitophagy in patients' ﬁbro-
blasts, increased LC3B staining in MD cells was shown by immunoﬂuo-
rescence. Therefore, we determined the basal levels of autophagy by
Western blot analysis of LC3B in total cell lysates. Higher levels of
LC3B-II, the LC3 form associated with autophagosomes, were found in
patients' cell lines (Mann–Whitney test P= 0.013 for patients vs. con-
trols) (Fig. 5A andB). These results indicate higher autophagosome con-
tent in the cells fromMD patients. Normal range of LC3B in six different
control cell lines is shown in Fig. 5C with two MD cells (P1 and P4) for
better comparison between patients and controls.
3.3. Autophagosome clearance is not altered in the autophagic response in
mitochondrial diseases but autophagic vacuoles are accumulated in ﬁbro-
blasts derived from MD patients
To analyze if the increased LC3B-II detected in patients' cells lysates
was due to a failure of lysosomal activity we treated the cells with pro-
tease inhibitors E64D and pepstatin A (Fig. 6). Control ﬁbroblasts treat-
ed with the protease inhibitors showed higher (+150%) amounts of
LCBII in comparison with vehicle-treated cells, as expected for normal
lysosomal-dependent autophagosome clearance. In most of the MD
cell lines we could detect milder increases in the mean LC3B-II/actin
ratio, but P1, P2 and P11 showed increases in mean LC3B-II/actin ratio
similar to those found in controls. Patients cell lines pooled showed
138% higher levels compared with controls. The statistical analysis of
the autophagosome clearance did not show statistical signiﬁcance be-
tween the behavior of MD and control cell lines (Mann–Whitney test
P= 0.315 for patients vs. controls).
We also studied the colocalization between LC3B and mitochondria
by immunoﬂuorescence in baﬁlomycin A1-treated cells to analyze if
under conditions of blocked lysosomal ﬂuxwe could detect higher levels
of mitophagy in MD cells compared with controls. After baﬁlomycin
treatment we did not detect any change in the colocalization between
mitochondria and autophagosomes in controls (Mander's coefﬁcients
are shown in Supplemental Table 1, and representative images of control
and P1-treated cells are shown in Supplemental Fig. 5). In MD cells after
baﬁlomycin A1 treatment Mander's coefﬁcient for the red channel was
slightly higher but remained very low and was similar to that in
baﬁlomycin-treated controls. These results indicate that there is a low
colocalization between mitochondria and autophagosomes, and rules
out the possibility that increased mitophagy in basal conditions in MD
cells could be masked by lysosomal degradation of mitochondria-
containing autophagosomes.
Transmission electron microscopy revealed that the most outstand-
ing feature of MD cells in the cryosectionswas a higher amount of cyto-
solic vacuoles (Fig. 7A), butwe could not ﬁnd evidences of alterations in
the mitochondrial ultrastructure of MD cells (Supplemental Fig. 6A).
Someof these vacuoles could be considered autophagosomes, and hard-
ly any contained mitochondria. The most abundant vesicles were
multilaminar bodies, vacuoles containing electrondense material and
vacuoles with a mixed appearance between both multilaminar bodies
and electrondense vacuoles (examples of these organelles are shown
in Supplemental Fig. 6B). These organelles covered extensive areas in
patients' cells and were often large. According to the morphology
criteria of Eskelinen these vacuoles were considered lysosomes, late or
Fig. 4. Immunoﬂuorescence to detect Parkin (green) and themitochondrialmarker complexVα subunit (red) in controlﬁbroblasts (C) andﬁbroblasts frompatientswith isolated complex
I deﬁciency (P1–P3), complex III deﬁciency (P4–P8), complex IV deﬁciency (P9, P10), and decreased mtDNA content (P11). Colocalized pixels are shown in white. Four different controls
were analyzed. 63× Plan-Apochromat objective.
1064 M. Morán et al. / Biochimica et Biophysica Acta 1842 (2014) 1059–1070degradative autophagic vacuoles (AVd) and vacuoles due to the fusion
between AVd and lysosomes, respectively [38–40]. The stereological
counting of AVd and AVd fused with lysosomes revealed increased
amounts of these organelles per μm2 in patients' cells in comparison
with control ﬁbroblasts (Fig. 7B) (Mann–Whitney test P b 0.01 for
patients vs. controls).
To conﬁrm that the higher amount of AVd in patients' cells was ac-
companied by higher amounts of lysosomes, we performed a Western
blot against the lysosomal marker LAMP-1 (Fig. 8A). The results obtain-
ed showed markedly higher levels of this glycoprotein in all patients'
cells in comparison to controls (Mann–Whitney test P= 0.016 for pa-
tients vs. controls (Fig. 8B)). Normal range of LAMP-1 levels in 6 differ-
ent controls are shown in Fig. 8C with 2 MD cells (P1 and P4) for better
comparison between patients and controls.
In addition, speciﬁc lysosome staining with the Lysotracker™ DND-
26 in living cells, showed by confocal microscopy higher lysosomal con-
tent in MD ﬁbroblasts (Fig. 9) (Mann–Whitney test P= 0.007 patients
vs. controls). These results support the idea that higher than normal
amounts of lysosomes are present in mD patients' derived ﬁbroblasts.3.4. mTORC1 activity is not decreased in ﬁbroblasts derived from MD
patients
To further analyze the state of the autophagic pathway in MD cells,
we determined the phosphorylation levels of P70S6 kinase at threonine
389, which is a direct target of mTORC1, a protein complex that
negatively regulates autophagy. The results obtained are shown in
Supplemental Fig. 7. The ratio of phosphorylated p70 S6 kinase/total
p70 S6 kinase tended to be higher in most patients' cells in comparison
with controls, but the analysis did not reach statistical signiﬁcance
(Mann–Whitney test P N 0.05 for patients vs. controls). These results
suggest that there is no inhibition of mTORC1 in patients' ﬁbroblasts.4. Discussion
We have shown that mitophagy is not increased in ﬁbroblasts har-
boring defects in the OXPHOS system but autophagosomes, lysosomes
and late autophagic vacuoles are accumulated. This phenomenon
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to a pseudo-starvation response, or to an alteration of the autophagic
degradation pathway due to disturbances in some steps of the lysosom-
al degradation route leading to the accumulation of partially degraded
cellular materials.
Abolished mitochondrial membrane potential due to protonophore
treatment causes the recruitment of Parkin to mitochondria to mediate
their elimination by the autophagicmachinery in order tomaintain bio-
energetic efﬁciency in the cell [42]. Decreases in mitochondrial mem-
brane potential have been previously reported in cells from patients
with OXPHOS disorders suggesting that increased mitophagy could
also occur in MD models [14–18]. In our work only 2 cell lines showed
lower than normal ΔΨ, and similar results were described previously
by Iuso et al., who found, either no alterations or lowerΔΨ, inﬁbroblasts
from complex I-deﬁcient patients [13]. Perhaps the fact that the de-
creases in ΔΨ in our MD cells were milder than full depolarization
could be the cause of the absence of mitophagy. However, we have pre-
viously demonstrated in P1 and P3 that after mitochondrial depolariza-
tion and fragmentation, mitochondrial network fusion, a phenomenon
dependent on ΔΨ recovery, was delayed in comparison with control
cells, indicating that OXPHOS deﬁciencies cause slower kinetics of ΔΨ
recovery [26]. Therefore, the determination ofΔΨ in steady-state condi-
tions cannot always reveal dynamic alterations of ΔΨ occurring in MD
cells that could lead to increased mitophagy. Despite the heterogeneity
of the MD cell lines analyzed in the present work (i.e., with differences
in ΔΨ alteration, in the severity of the respiratory defect, isolated deﬁ-
ciencies in some patients vs. combined defects in others, or mutations
in nuclear DNA vs. mutations in mtDNA), we detected overall higher
than normal levels of the autophagosomal marker LCB-II in all MD
cells, suggesting increased autophagy, as previously reported in other
models of MD (17–22). Therefore, enhancement of autophagosome
content but not increased mitophagy might be a general cellularresponse to OXPHOS defect that occurs independently of ΔΨ and of
the severity of the OXPHOS defect.
The previous studies in primary cultures of ﬁbroblasts derived from
patients with OXPHOS disorders have described increased mitophagy
[19–21]. The discrepancies between these studies and the present ﬁnd-
ings could be due to the different consequences at cellular level of the
OXPHOS disorder shown between the cells studied. For instance, in
the studies by Sanchez-Alcazar's group all MD cells showed coenzyme
Q deﬁciency, combined respiratory chain deﬁciency, decreased ΔΨ,
mitochondrial fragmentation, increased levels of oxidative stress even-
tually leading to opening the mitochondrial transition pore, and
evidences of autophagy induction, such as increased Atg5 and Beclin
levels [19–21]. In the present investigation none of the analyzed MD
cells showed concurrently those alterations, i.e. none presented with
decreased ΔΨ, increased ROS levels and mitochondrial fragmentation
at the same time [26,30]. Moreover, in the MD cells analyzed in the
present work we failed to detect changes in Atg5–Atg12, and prelimi-
nary data from our laboratory suggest the absence of increased phos-
phorylation of ULK1 at Ser555 (data not shown), indicating that the
initial steps of the autophagic cascade are not induced. It is tempting
to speculate that several signals of mitochondrial damage, as strong de-
polarization and increasedmitochondrial ROS production are needed to
induce mitophagy. In this regard, it has been reported that both, loss of
mitochondrialΔΨ andmTORC1 inhibition, are needed synergistically to
induce mitophagy in cells carrying pathogenic mtDNA mutations [43].
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Fig. 7. A) Electron microscopy of ultrathin sections of control ﬁbroblasts (C) and ﬁbroblasts derived from MD patients with isolated complex I deﬁciency (P1–P3), complex III
deﬁciency (P5, P6, P8), complex IV deﬁciency (P9), and decreased mtDNA content (P11). Examples of late or degradative autophagic vacuoles (AVd) are depicted by arrow-
heads. Images shown are tiling of 2 × 3 or 3 × 3, 8 K individual images. B) Stereological counting of AVd expressed as AVd/μ2, data are presented as mean ± SD. Four different
controls were analyzed. Mann–Whitney test P b 0.01 for patients vs. controls.
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A, at concentrations to induce mild mitochondrial alterations, showed
increased autophagy but nomitophagy [44]. Further studies are needed
to unveil the different autophagic response found in OXPHOS-deﬁcient
cells and the trigger(s) responsible for such phenomenon. On the other
hand, it has been shown that cells can spare their mitochondria from
degradation even after autophagy induction [45–47]. Mitochondria are
key organelles for cell survival; therefore, despite their OXPHOS defects,
cells may keep mitochondria out of degradation, preventing a futile
cycle of biogenesis and elimination of these vital organelles in a cellular
context of lack of energy.
In contrast to the previous studies indicating that Parkin labels
depolarized mitochondria to initiate mitophagy, we have shown the
absence of Parkin-drivenmitophagy even in those cell lineswith dimin-
ishedΔΨ. These discrepancies could be due to differences in themodelsof study employed, i.e., strong mitochondrial depolarization with
protonophores vs. milder depolarization conditions due to OXPHOS de-
fects, overexpression of Parkin vs. endogenous levels of the protein, or
use of cultured cell lines vs. primary cultures [8,42,48–50]. Other au-
thors using primary mammalian cell cultures, such as cortical neurons,
have also failed to show Parkin-mediated mitophagy, even after CCCP-
induced mitochondrial depolarization despite signiﬁcant Parkin locali-
zation tomitochondria [51]. In primary ﬁbroblasts from Parkinson's dis-
ease patients harboring PINK1 mutations (a model in which alterations
of Parkin behavior are expected) additional external stress stimuli, such
as valinomycin treatment, is needed to visualize differences in Parkin
levels and its translocation to mitochondria between control and mu-
tant cells [52].Moreover, it has been reported that in dopaminergic neu-
rons ofMitoParkmice, dysfunctionalmitochondria do not recruit Parkin
in vivo, and neither the clearance of dysfunctional mitochondria nor the
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sence of Parkin [53]. In the present work we found Parkin labeling not
only in small dotted mitochondria (that may be partly depolarized),
but also in those expected to have normal mitochondrial potential
showing tubular shape, in both controls' and patients' derived cells.
These ﬁndings are in agreement with the previous data showing that,
under basal conditions, Parkin exists in the cytoplasm and also directly
associated with mitochondria [51,54–57]. Also, in trans-mitochondrial
cybrid cells genetically- and chemically-induced loss of ΔΨ triggered
Parkin recruitment to mitochondria without causing mitophagy [43].
Given that mitochondrial Parkin localization was slightly higher in
some MD patients' cells without inducing mitophagy, Parkin could be
maybe mediating some additional functions different from mitochon-
drial labeling for autophagy. In fact, several Parkin roles related to
mitochondrial function have been reported [55,56]. For instance, mito-
chondrial localized Parkin is able to prevent CCCP-induced mitochon-
drial depolarization in COS-1 and HeLa cells [57]. Interestingly Vincow
et al. demonstrated that Parkin mediates selective non-mitophagic
turnover of mitochondrial respiratory chain proteins in Drosophila
in vivo [58], and it has been proposed that some respiratory chain com-
plexes, such as complex I, may be especially labile and would require
more frequent turnover than other components [59]. Thus, in complex
I-deﬁcient cell lines the increased mitochondrial Parkin recruitment to
mitochondria could be maybe related to a role of this protein in
mitochondrial membrane potential maintenance under bio-energetic
stress conditions, or also in the event of increased respiratory chain
component turnover due to altered folding of the mutated subunits, in-
stability or disassembly of respiratory complexes. Findings obtained in
autophagy-defective yeast mutants have shown that the supply of
amino-acids via bulk autophagy, but not selective autophagy, isimportant for the maintenance of respiratory chain function during
starvation [60]. Despite the evolutionary distance between yeast and
mammalian cells, these results could suggest that in MD cells, which
are under bio-energetic stress conditions and probably under proteina-
ceous stress due to altered respiratory complexes assembly, autophagy
of cytoplasmic material might also be needed to maintain increased
turnover of respiratory chain subunits and complexes.
Although autophagy has receivedmore recent attention as a route to
clear dysfunctional organelles, it has been known for many years that
autophagy is an important survival mechanism during short-term
starvation to degrade non-essential components in order to obtain nu-
trients for vital biosynthetic reactions [37]. Several studies have de-
scribed starvation-like response in mouse models of MD and human
muscle from patients harboring m.8344 A N G mutation [22,23,61,62].
Although MD patients, MD animals or MD cellular models are not
under starvation conditions, their bio-energetic defect prevents them
from obtaining high enough ATP levels to maintain normal cellular
functions [26,30]. Low levels of ATP in patients' cells could trigger au-
tophagy due to the inhibition of mTORC1 by the activation of AMPK,
but our preliminary results suggested no inhibition of mTORC1 in the
MD cells (Supplemental Fig. 1). Perhaps, persistent autophagy induction
in our model of disease due to chronic low ATP could cause reactivation
of mTOR as previously reported by Yu et al. in rat kidney cells [63]. New
insights in the regulation of the autophagic response in yeast have been
recently reported by Graef and Nunnari, who proposed that mitochon-
drial function canmodulate autophagy independently ofmTOR through
PKA, by affecting both ATG gene induction and the autophagic ﬂux (via
assembly of Atg into the pre-autophagosomal structures) [64]. The
authors proposed that mitochondrial dysfunction blocks both autopha-
gy induction and autophagic ﬂux, and that the response induced may
vary depending on the nature and severity of the mitochondrial defect,
i.e., collapse of mitochondrial membrane potential vs. only respiratory
chain defect. If this regulatory mechanism could also be applied to
mammalian cells, we would expect both the inhibition of the autopha-
gic ﬂux and of Atg induction in the MD cells studied in the present
work. Thiswould explain the poor response of theMD cells to lysosomal
inhibitors, while LC3B-II accumulation would result of partially blocked
lysosomal ﬂux. Nevertheless, as the autophagosomal ﬂux was only
partially hampered in our MD cells, the direct assessment of mTORC1
activity and an in-depth study of the signaling pathways involved in
autophagy regulation could help unveil the mechanisms of autophagy
regulation in our cellular model of disease.
Decreases in ATP levels can also block the autophagy ﬂux indepen-
dently of mTORC1 because ATP is required in the sequestration step as
well as to maintain lysosomal function [65–69]. Taken into account
that mTORC1 seemed to be active but the amount of AVd was signiﬁ-
cantly increased in our MD cells, we could hypothesize that in ﬁbro-
blasts harboring OXPHOS defects, autophagic ﬂux could be partially
hampered by the lack of energy. This possibility may explain that after
lysosomal inhibition LC3B-II was only slightly increased in patients'
ﬁbroblast. Similar resultswere found in OXPHOS deﬁcient cells frompa-
tients presenting MELAS in which ATP was decreased and baﬁlomycin
treatment did not rise LC3B-II levels [20]. Consequently, in OXPHOS de-
ﬁcient cells, abnormalities in the lysosomal degradationmay contribute
to autophagosome and AVd accumulation.
In conclusion, in a cellular model of disease, OXPHOS deﬁciencies
result in the accumulation of autophagic vacuoles and lysosomes. This
vesicular trafﬁc-jammay interfere with normal cellular function further
contributing to the disease. Future studies analyzing the regulation of
autophagy-related signaling cascades in cellular models of disease,
and proving the existence of similar alterations in target human tissues
affected by these diseases, i.e., skeletal muscle, are needed to gain
insights into the disturbances of autophagy and its contribution to
human OXPHOS disorders.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.03.013.
Fig. 9. A) Lysosomal content in living cells stained with Lysotracker® DND-26: control ﬁbroblasts (C), ﬁbroblasts from patients with isolated complex I deﬁciency (P1, P2), complex III
deﬁciency (P4–P8), complex IV deﬁciency (P9), and decreasedmtDNA content (P11). Cells were viewedwith a Zeiss LSM 510Meta confocal microscopewith a 40× Plan-Neoﬂuar objec-
tive. B) Quantitative analysis of Lysotracker® DND-26 staining intensity in control (C) and MD cells (P1–P11). Four different controls were analyzed. Mann–Whitney test P= 0.007 for
patients vs. controls.
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